Tags

Type your tag names separated by a space and hit enter

Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Transplantation. 2012 Mar 15; 93(5):536-42.T

Abstract

BACKGROUND

Several studies proved that virus-specific T-cells play a pivotal role in controlling cytomegalovirus (CMV) infection in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients. Fewer data are available in pediatric HSCT settings, when immature and inexperienced immune system may affect antiviral immune reconstitution.

METHODS

We analyzed prospectively the CMV-specific T-cell reconstitution in a cohort of 31 pediatric allogeneic HSCT recipients at 30, 60, 90, 120, 180, and 360 days after HSCT.

RESULTS

Depending on donor-recipient CMV serostatus, we observed distinct patterns and kinetics of CMV-specific T-cell immune reconstitution: during the early time-points, patients displayed a severe reduction in CMV-specific T-cell recovery in both CMV seropositive donor (D+) group and CMV seronegative donor (D-) on CMV seropositive recipients (R+). From day 90 onward, statistical significant differences in the profile of T-cell immune reconstitution emerged between D+ and D-. The pattern of immune reconstitution was characterized by heterogeneous kinetics and efficiencies: we report cases of: (1) spontaneous antiviral T-cell recovery with no previous viremia, (2) immune T-cell recovery anticipated by CMV viremia, and (3) no T-cell immune reconstitution despite previous viremia episodes.

CONCLUSIONS

Given the heterogeneous scenarios of antiviral T-cell immune recovery in pediatric allogeneic HSCT, we conclude that the evaluation of the antiviral immune reconstitution is a promising and appealing system for identifying patients at higher risk of CMV infection. The use of interferon-γ ELISPOT test is a valid tool for immunological monitoring and predicting CMV viremia in pediatric HSCT.

Authors+Show Affiliations

Department of Histology, Microbiology and Medical Biotechnology, University of Padua, Padova, Italy. davide.abate@unipd.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22314338

Citation

Abate, Davide, et al. "Diagnostic Utility of Human Cytomegalovirus-specific T-cell Response Monitoring in Predicting Viremia in Pediatric Allogeneic Stem-cell Transplant Patients." Transplantation, vol. 93, no. 5, 2012, pp. 536-42.
Abate D, Cesaro S, Cofano S, et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation. 2012;93(5):536-42.
Abate, D., Cesaro, S., Cofano, S., Fiscon, M., Saldan, A., Varotto, S., Mengoli, C., Pillon, M., Calore, E., Biasolo, M. A., Cusinato, R., Barzon, L., Messina, C., Carli, M., & Palù, G. (2012). Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation, 93(5), 536-42. https://doi.org/10.1097/TP.0b013e31824215db
Abate D, et al. Diagnostic Utility of Human Cytomegalovirus-specific T-cell Response Monitoring in Predicting Viremia in Pediatric Allogeneic Stem-cell Transplant Patients. Transplantation. 2012 Mar 15;93(5):536-42. PubMed PMID: 22314338.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. AU - Abate,Davide, AU - Cesaro,Simone, AU - Cofano,Simona, AU - Fiscon,Marta, AU - Saldan,Alda, AU - Varotto,Stefania, AU - Mengoli,Carlo, AU - Pillon,Marta, AU - Calore,Elisabetta, AU - Biasolo,Maria Angela, AU - Cusinato,Riccardo, AU - Barzon,Luisa, AU - Messina,Chiara, AU - Carli,Modesto, AU - Palù,Giorgio, PY - 2012/2/9/entrez PY - 2012/2/9/pubmed PY - 2012/4/17/medline SP - 536 EP - 42 JF - Transplantation JO - Transplantation VL - 93 IS - 5 N2 - BACKGROUND: Several studies proved that virus-specific T-cells play a pivotal role in controlling cytomegalovirus (CMV) infection in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients. Fewer data are available in pediatric HSCT settings, when immature and inexperienced immune system may affect antiviral immune reconstitution. METHODS: We analyzed prospectively the CMV-specific T-cell reconstitution in a cohort of 31 pediatric allogeneic HSCT recipients at 30, 60, 90, 120, 180, and 360 days after HSCT. RESULTS: Depending on donor-recipient CMV serostatus, we observed distinct patterns and kinetics of CMV-specific T-cell immune reconstitution: during the early time-points, patients displayed a severe reduction in CMV-specific T-cell recovery in both CMV seropositive donor (D+) group and CMV seronegative donor (D-) on CMV seropositive recipients (R+). From day 90 onward, statistical significant differences in the profile of T-cell immune reconstitution emerged between D+ and D-. The pattern of immune reconstitution was characterized by heterogeneous kinetics and efficiencies: we report cases of: (1) spontaneous antiviral T-cell recovery with no previous viremia, (2) immune T-cell recovery anticipated by CMV viremia, and (3) no T-cell immune reconstitution despite previous viremia episodes. CONCLUSIONS: Given the heterogeneous scenarios of antiviral T-cell immune recovery in pediatric allogeneic HSCT, we conclude that the evaluation of the antiviral immune reconstitution is a promising and appealing system for identifying patients at higher risk of CMV infection. The use of interferon-γ ELISPOT test is a valid tool for immunological monitoring and predicting CMV viremia in pediatric HSCT. SN - 1534-6080 UR - https://www.unboundmedicine.com/medline/citation/22314338/Diagnostic_utility_of_human_cytomegalovirus_specific_T_cell_response_monitoring_in_predicting_viremia_in_pediatric_allogeneic_stem_cell_transplant_patients_ L2 - https://doi.org/10.1097/TP.0b013e31824215db DB - PRIME DP - Unbound Medicine ER -